Drugs / Sucrase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04604275 | Jan 2022 → Sep 2024 | short bowel syndrome | University of Miami | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sucrase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04604275 ↗ |
| Modality | Protein / enzyme biologic | “exogenous sucrase (enzyme)” NCT04604275 ↗ |
| Route | Oral | “taken orally or by g-tube” NCT04604275 ↗ |
| Route | Other | “taken orally or by g-tube” NCT04604275 ↗ |